Sign In
Buy INCY
$119.80
-0.800 (-0.663%)
At Close: Aug 05, 2026
Incyte: Time Again To Wait And Watch
12:43pm, Friday, 31'st Jul 2020
Incyte has the potential to provide high adjusted non-GAAP EPS growth, together with high P/E multiple, resulting in a strong share price growth.
FDA Approves Monjuvi® (tafasitamab-cxix) in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed or Refractory DLBCL
10 Biggest Biotechnology Companies
11:32pm, Thursday, 30'th Jul 2020
With Novo Nordisk at the top of the list, these are the 10 biggest biotechnology companies by 12-month trailing revenue.
Incyte (INCY) Earnings Expected to Grow: Should You Buy?
04:33pm, Tuesday, 28'th Jul 2020
Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is a Beat in the Cards for Incyte's (INCY) Q2 Earnings?
03:40pm, Tuesday, 28'th Jul 2020
Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Incyte (INCY) reports second-quarter 2020 results.
Incyte (INCY) Earnings Expected to Grow: Should You Buy?
12:33pm, Tuesday, 28'th Jul 2020
Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is a Beat in the Cards for Incyte's (INCY) Q2 Earnings?
11:40am, Tuesday, 28'th Jul 2020
Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Incyte (INCY) reports second-quarter 2020 results.
Does Incyte's (NASDAQ:INCY) CEO Salary Compare Well With Industry Peers?
05:54pm, Monday, 27'th Jul 2020
Hervé Hoppenot became the CEO of Incyte Corporation (NASDAQ:INCY) in 2014, and we think it's a good time to look at...
William Blair Reaffirms Buy Rating for Incyte (NASDAQ:INCY)
03:14am, Monday, 27'th Jul 2020
William Blair reaffirmed their buy rating on shares of Incyte (NASDAQ:INCY) in a research report sent to investors on Friday, AnalystRatings.com reports. A number of other equities research analysts h
5 High-Yield Drug Stocks That Are Undervalued With Great Upside
06:06pm, Friday, 24'th Jul 2020
These five high yield drug stocks pay dividends with attractive yields, and also are undervalued. And as a result, these stocks offer good upside potential to investors. As a group, they are cheap. Ye
Incyte Announces REACH3 Trial of Ruxolitinib (Jakafi®) in Patients with Chronic Graft-Versus-Host Disease Met Primary and Both Key Secondary Endpoint
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces REACH3 Trial of Ruxolitinib (Jakafi®) in Patients with Chronic Graft-Versus-Host Disease Met Primary and Both Key Secondary Endpoint
Vident Investment Advisory LLC Purchases New Stake in Incyte Co. (NASDAQ:INCY)
07:44am, Wednesday, 22'nd Jul 2020
Vident Investment Advisory LLC purchased a new stake in shares of Incyte Co. (NASDAQ:INCY) in the 2nd quarter, Holdings Channel reports. The fund purchased 15,147 shares of the biopharmaceutical compa
Incyte Co. (NASDAQ:INCY) Shares Sold by Redpoint Investment Management Pty Ltd
06:56am, Wednesday, 22'nd Jul 2020
Redpoint Investment Management Pty Ltd lowered its holdings in Incyte Co. (NASDAQ:INCY) by 25.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commiss
Dow Leads the Way as the Market's Focus Flips
12:00am, Wednesday, 22'nd Jul 2020
Stocks Analysis by Zacks Investment Research covering: Microsoft Corporation, Alphabet Inc Class A, Las Vegas Sands Corp, Nike Inc. Read Zacks Investment Research's latest article on Investing.com
